Human tumor antigens recognized by T cells and their implications for cancer immunotherapy

Ryo Ueda, Tomonori Yaguchi, Yutaka Kawakami

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70% of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.

Original languageEnglish
Title of host publicationInnate Immune Regulation and Cancer Immunotherapy
PublisherSpringer New York
Pages335-345
Number of pages11
ISBN (Print)9781441999146, 9781441999139
DOIs
Publication statusPublished - 2012 Jan 1

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ueda, R., Yaguchi, T., & Kawakami, Y. (2012). Human tumor antigens recognized by T cells and their implications for cancer immunotherapy. In Innate Immune Regulation and Cancer Immunotherapy (pp. 335-345). Springer New York. https://doi.org/10.1007/9781441999146_19